Form SCHEDULE 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]
SEC Accession No. 0001415889-25-024279
Filing Date
2025-09-11
Accepted
2025-09-11 16:25:00
Documents
2

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13D/A  
1 primary_doc.xml SCHEDULE 13D/A 25049
2 JOINT FILING AGREEMENT ex-99-09112025_080957.htm EX-99.1 7010
  Complete submission text file 0001415889-25-024279.txt   33804
Mailing Address ONE KENDALL SQUARE BUILDING 1400 WEST, 3RD FLOOR CAMBRIDGE MA 02139
Business Address ONE KENDALL SQUARE BUILDING 1400 WEST, 3RD FLOOR CAMBRIDGE MA 02139 617-651-8867
Camp4 Therapeutics Corp (Subject) CIK: 0001736730 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13D/A | Act: 34 | File No.: 005-94655 | Film No.: 251308808
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)

Mailing Address 4 EMBARCADERO CENTER, SUITE 3110 SAN FRANCISCO CA 94111
Business Address 4 EMBARCADERO CENTER, SUITE 3110 SAN FRANCISCO CA 94111 (415) 993-8565
5AM Ventures VI, L.P. (Filed by) CIK: 0001753037 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13D/A